Drugs / Apalotamab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07082179 | Sep 2025 → Dec 2027 expected | non-small cell lung carcinoma | Jiangsu Cancer Institute & Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apalotamab | “Apalotamab: 5 mg/kg, every 3 weeks (q3w), administered via intravenous infusion” NCT07082179 ↗ |